| Ytd | 0.53% | |
| 1y | 86.14% |
| Open | 3.79 | Prev Close | 3.78 | Low | 3.67 | High | 3.79 | Mkt Cap | 342.11M |
| Vol | 0.00 | Avg Vol | 720.92K | EPS | -1.30 | P/E | -2.89 | Forward P/E | -1.56 |
| Beta | 0.64 | Short Ratio | 1.22 | Inst. Own | 34.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.67 | 200-d Avg | 3.76 | 1yr Est | 12.40 |
SABS News
SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in new
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset t
Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have earned a consensus rating
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D)
Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst r
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully h
Wall Street analysts changed outlook on top names. See full ratings page for upgrades, downgrades, a
SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on tr
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage b
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants
SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candida
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Hall
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollm
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) has received a consensus rating of "Moder
Viking Therapeutics (NASDAQ: VKTX - Get Free Report) and SAB Biotherapeutics (NASDAQ: SABS - Get Fre
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D.
Monday's session saw 114 companies set new 52-week lows.
On Friday, 93 stocks made new 52-week lows.
On Wednesday, 81 companies hit new 52-week lows.
During Tuesday, 95 stocks hit new 52-week lows.
On Monday, 89 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
On Tuesday, 400 companies set new 52-week lows.
On Thursday, 529 companies set new 52-week lows.
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Sc
Wednesday's session saw 269 companies set new 52-week lows.
On Friday, 422 stocks made new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
Wednesday's session saw 107 companies set new 52-week lows.
During Wednesday's morning trading, 400 companies set new 52-week lows.
Tuesday morning saw 454 companies set new 52-week lows.
During Friday's session, 445 companies made new 52-week lows.